MM45289 (A82846A, eremomycin), a glycopeptide antibiotic of the vancomycin type, was confirmed to have improved antibacterial activity over vancomycin. However its affinity (Ka) for the target site peptide mimetic diacetyl-L-lysyl-D-alanyl-D-alanine (DALAA) was 23-fold lower. Concentrations of DALAA required to reverse the antibacterial activity of MM 45289 were in the order of 10 to 50-fold higher than for vancomycin. These results have implications for both mode of action studies and mechanism-basedscreening strategies for this class of antibiotic.
substrate for the transpeptidation reaction necessary for the formation of a rigid cell wall structure5*. Much work has been published on the nature of this binding and recently it was established that the affinity of close analogues of vancomycin for a model peptide ligand (diacetyl-L-lysyl-D-alanyl-D-alanine: DALAA) correlated with their antibacterial potency6). Indeed, the ability of glycopeptides to bind to DALAA prompted the design of a highly specific, mechanism-based screen using reversal or antagonism of antibacterial activity by DALAAto detect producers of this class of antibiotic from soil samples7).
In this paper we report on the antibacterial activity of MM45289 and its interaction with DALAA. The relevance of these results to the use of the DALAA reversal screen in the search for newglycopeptide antibiotics is also discussed.
Materials and Methods
Antibiotics and Other Reagents
(AILAA) and vancomycin were obtained from Sigma. MM45289 was isolated from A. orientalis NCIB 1253 1 at Brockham Park; its structure being identical to that reported for A82846A and eremomycin (M. Gilpin; personal communication).
Determination of Antibiotic MIC
The activity ofvancomycin and MM45289 against 36 clinical isolates ofcoagulase-positive and negative Staphylococci and against Bacillus subtilis ATCC6633 were assessed by conventional agar and broth microdilution MIC tests. The media used were nutrient, Isosensitest and Diagnostic Sensitivity Test (DST) agars and Isosensitest (1ST) broth and Nutrient Broth No. 2 (Oxoid). Inocula were prepared from 18-hour broth cultures and contained between 105 to 106 cfu. MICs were read after 1 8 hours at 37°C incubation.
Potentiation and Antagonism of Antibacterial Activity
The effect ofpeptide ligands on the antibacterial activity ofvancomycin and MM45289 was investigated using agar zone diffusion assays and broth microdilution tests. Paper disc diffusion assays with B. subtilis ATCC6633 were carried out exactly as described by Rake et alJ\ using 100 fig DALAAper disc. Diffusion assays with Staphylococcus aureus W8184,a clinical isolate, were carried out on DSTagar; glycopeptides and DALAA being added to 7mmwells cut in the agar (80/A volume). Inhibition zones were measured after 18 hours at 37°C and glycopeptide potency calculated by reference to inhibition zone diameters of standard concentrations of glycopeptide. Conventional checkerboard broth microdilution tests employing serial 2-fold dilutions of glycopeptide and peptide ligand were carried out in 1ST broth. The components were stored in the microtitre trays for 18 hours at 4°C before bacteria at 106cfu/well were inoculated. Glycopeptide MICsfor each concentration of ligand were read after a further 18 hours at 37°C. UV Difference Spectroscopy Antibiotic solutions (2.5ml at 0.136mM in 0.02m sodium citrate buffer, pH 5.2) were placed in the sample and reference cells ofa Perkin Elmer 554 spectrophotometer. DALAA (1~20 fi\ of 33.6 mMsolution) was added to the sample cell and buffer to the reference cell. The magnitude of the difference in absorbance between 282 and 293 nm was measured at 25 + 2°C. Association constants were then deduced from Scatchard plots assuming a simple equilibrium: Glycopeptide + peptide = glycopeptide-peptide complex8). Antibiotic concentrations were determined by UVwith a value of El^m=45.0 at 280nm for both vancomycin and MM45289.
Results

Antibacterial
Activity of Vancomycin and MM45289 MM45289 was consistently more active than vancomycin against Staphylococci and B. subtilis in a range of different media (Table 1) . Little difference in the susceptibility of the various staphylococcal strains was observed, as evidenced by the narrow range of MICs obtained. The difference between MM45289 and vancomycin MICs tended to be greater in broth than on agar.
Effect of DALAAon Glycopeptide Potency Estimated by Bioassay
In preliminary agar diffusion assays using S. aureus W8184, 100/ig DALAAcompletely abolished the inhibition zone surrounding a paper disc containing 12.5fig vancomycin. However, the same concentration of DALAA tended to increase the zone diameter around a similar disc of MM45289. This phenomenonwas studied further; results being expressed in terms of antibacterial potency relative to that of standards without DALAA (Fig. 2) . As expected, the amount of DALAA required to antagonise vancomycin increased with the concentration of glycopeptide. At none of the concentrations tested did DALAApotentiate the activity of vancomycin. In marked contrast, DALAAdid potentiate the activity of MM45289 by between 20 and 90%. At higher concentrations, DALAAantagonised the activity of MM45289. The concentration at which it did so was between 10 and 20 times that required for similar concentrations of vancomycin.
Similar results were seen using the previously published mechanism-based screen employing B. subtilis. DALAA(100^g) reduced the zone of inhibition around vancomycin discs but enhanced that around discs containing MM45289 (Fig. 3) . Furthermore, paper discs dipped in the culture medium from A. orientalis. NCIB 12531 also gave an increased zone diameter in the presence of DALAA (Fig. 3) .
Effect of DALAA and Two Pentapeptides on Glycopeptide MICs Reversal experiments were also carried out in conventional microdilution susceptibility tests with S. aureus W8184 and B. subtilis ATCC6633. Again, the activity of MM45289 was less affected by DALAA than that of vancomycin. The lowest concentration of DALAA which resulted in an increase in the MIC of MM45289 was approximately ten to fifty times that affecting vancomycin MICs (Fig. 4) . No evidence ofpotentiation ofMM45289 by DALAA was seen in terms ofa decrease in MIC. Preliminary microdilution MICtests with two other peptide ligands (AILAAand AGLAA) gave results similar to those with DALAA ( W8184 from 2 to >64/xm (>32-fold) whereas the MIC of MM45289 was raised from 1 to 4/xm (AGLAA) or 8 /xm (AILAA and DALAA).
UVDifference Spectroscopy Representative Scatchard plots are shown in Fig. 5 from which DALAA affinity constants for MM 45289 and vancomycin were obtained. The meanKa value from repeated experiments for vancomycin was 0.913 x lO6]^"1 (standard deviation=0.213 x 106; n=3) and that for MM45289 was 0.039 x lO6*!"1 (standard deviation=0.009 x 106; 72=6); a 23-fold difference in affinity.
Discussion
Vancomycin and MM45289 share the same heptapeptide nucleus but differ in the number of chlorine atoms, the stereochemistry of the basic sugar moiety in the central disaccharide unit (e/?z-vancosamine in MM45289) and, in MM45289, the presence of a second epz-vancosamine moiety attached directly to the heptapeptide. These differences result in MM45289 being more active than vancomycin in vitro; a finding consistent with other studies4'9). However, its interaction with the tripeptide DALAA, the two pentapeptides AILAA and AGLAA,and its affinity for DALAA, are much reduced.
There was good quantitative agreement between the antibacterial reversal data and relative affinity constant calculated by UV absorbance changes. The reversal experiments indicated that the amount of DALAA required to reverse the activity of MM45289 was 10-20 (zone diffusion) and 10~50 (microdilution MIC) times that required for vancomycin. The difference in calculated Ka's was 23-fold.
The lack of correlation between MIC and DALAAaffinity for vancomycin and MM45289 implies that this tripeptide is limited in its use as a simple model of the glycopeptide peptidoglycan target. The poor reversal of MM45289 activity by AILAAand AGLAA suggest that the same may be true for these pentapeptides. The possibility that MM 45289 has a second modeof action is unlikely since it is active against neither L-form Staphylococci nor Enterococci expressing the 39 Kd vancomycin resistance determinant specific for glycopeptide antibiotics1 0) (unpublished observations). The potentiation of MM45289 activity by low concentrations of DALAA, revealed in agar diffusion tests, was unexpected. The level of potentiation was slight; less than 2-fold and therefore not expected to show up in conventional MICtests. The mechanism(s) underlying this potentiation are not known but possible explanations include cooperative interaction with cell wall precursors in the presence of exogenous ligand. Alternatively, since DALAA is a substrate for purified staphylococcal transpeptidase1 1}, it may be able to undergo a similar reaction in vivo. This would result in a reduction in peptidoglycan cross-linking and may synergise with glycopeptide activity. Such synergy with DALAA would be seen with glycopeptides such as MM45289, which are highly potent and yet have a low affinity for the ligand. However, glycopeptides with a higher affinity for DALAA such as vancomycin would not be expected to show such synergy; both their own intrinsic activity and the ligand's involvement in transpeptidation reactions being mutually inhibited.
Whatever the reason for the observed potentiation between MM45289 and DALAA on bioassay, the failure of the mechanism-based DALAA reversal screen to detect MM45289 in the culture medium of the producer culture (Fig. 3 ) is significant. Modification of such an approach would appear to be indicated in order to ensure the detection of glycopeptides, such as MM45289, with potent antibacterial activity coupled with a poor affinity for DALAA.
